Can galeterone show effectiveness in men with AR-V7 mCRPC?

According to a report in The ASCO Post last night, the investigational drug galeterone may have significant clinical activity against a specific subtype of castration-resistant prostate cancer (CRPC) known as AR-V7. … READ MORE …

Combination immunotherapy for men with mCRPC: another new trial proposed

Late yesterday, Advaxis Immunotherapies announced the potential initiation of human trials of another new form of immunotherapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Does olaparib have real potential in treatment of mCRPC?

According to a report on the Reuters web site yesterday, some researchers are of the opinion that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (recently recommended for approval in Europe for the treatment of a subset of women with ovarian cancer) may be valuable in the treatment of some forms of prostate cancer too. … READ MORE …

Two different “takes” from the results of the CHAARTED trial

In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …

Evolution of the mCRPC treatment landscape

A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

KPT-330 in treatment of mCRPC

Earlier this year, Karyopharm Therapeutics initiated a Phase II clinical trial of KPT-330 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed on treatment with drugs like abiraterone acetate and enzalutamide. … READ MORE …

“Final” data on abiraterone acetate in treatment of chemo-naive mCRPC

According to a media release issued on Sunday, the most recent “final” update to the COU-AA-302 trial has shown that treatment with abiraterone + prednisone provided a statistically significant overall survival benefit in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,173 other followers